

In the Claims:

21. (Previously presented) A method for the screening and identification of a compound which inhibits atherosclerosis or restenosis comprising the use of PDE4 as a target.

22. (Previously presented) The method of claim 21 wherein the PDE4D selected from the group consisting of PDE4D, PDE4DS and PDE4D7.

23. (Previously presented) The method of claim 22, wherein the PDE4 is PDE4D7.

24. (Previously presented) The method of claim 21 further comprising increasing the activation or inhibition of the phosphodiesterase activity of PDE4 by the compound.

25. (Previously presented) The method of claim 24, wherein the compound is an inhibitor of PDE4.

26. (Previously presented) The method of claim 25, wherein the PDE4 is selected from the group consisting of PDE4D, PDE4D5 and PDE4D7.

27. (Previously presented) A process for identifying and obtaining a compound for therapy of atherosclerosis, or restenosis, said process comprising administering a compound suspected to be an activator or inhibitor of PDE4 to a non-human animal in which atherosclerosis or restenosis is induced, and measuring the extent of atherosclerosis or restenosis as compared to control-treated animals.

28. (Previously presented) The process of claim 27, wherein said PDE4 is PDE4D.

29. (Previously presented) The process of claim 28 wherein the PDE4D is selected from the group consisting of PDE4D5 or PDE4D7.

30. (Previously presented) The process of claim 28 wherein the PDE4D is PDE4D7.

31. (Previously presented) The compound of claim 21.

32. (Previously presented) The compound of claim 25.

33. (Previously presented) The compound of claim 27.

34. (Previously presented) A pharmaceutical composition comprising the compound of claim 32 and a pharmaceutically acceptable isomer.

34. 35. (Currently Amended) A method for the treatment of PAOD comprising administering the pharmaceutical composition of claim 34 to a subject having PAOD.

35. 36.(Currently Amended) A pharmaceutical composition comprising the compound of claim 27 and a pharmaceutically acceptable isomer.

36. 37. (Currently Amended) A method for the treatment of PAOD comprising administering the pharmaceutical composition of claim 36 to a subject suffering from atherosclerosis or restenosis.